- Company
- Werewolf Therapeutics, Inc.
- Drug or asset
- WTX-330
- Indication
- Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
- Phase
- Phase 1b/2
- Status
- upcoming
HOWL biotech catalysts
Clinical-trial, drug-development and regulatory milestones for Werewolf Therapeutics, Inc..